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Background
• AML has been shown to be highly
dependent on the expression BCL
protein family
• BCL-2 inhibition has been shown to be
a potent modailty in AML treatment
• Thrombocytopenia in myelodysplasmic
syndromes range from 40-65%
• AML has a 30% 5-year prognosis
• 753B is a novel PROTAC
bioengineered to degradate the BCL
family, specifically BCL2 and BCLXL
• Coinically, 753B should have a
greater affinity for targeting AML cells
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Methods
We treated various AML cell lines
in vitro to observe the effects of
introduction to 753B. We used the
BioRad Western Blot system to




respective cell lineages. We then
ultilized a CTG assay to observe
rates of apoptosis induction in cell
lines exposed to different drugs at
identical concentrations. We used
imagestudio and microsoft excel
for data analysis and visulaization.
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Our experiments indicate that BCLXL is
consitently degradated upon exposure to
753B. BCL2 seems to show moderate levels
of degradation but tends to not be as
significant or consistnent as BCLXL.The
observed BCL2 resistance may be explained
by current research, which suggests
that certain cells lines which express highe
levels of TP73 show BCL2 inhibition
resistance. 753B also induces apoptosis at
rates greater than or compareable to current
drugs. Due to the specificity of 753B to AML
cells, compareable apopotic induction may
prove advantegous clinically, as the drug may










Aim 1: Prove that 753B is effective 
in BCL protein degradation
Aim 2: Indicate the efficacy of 753B 
in comparison to venetoclax, navitoclax, DT2216
